Nisa Investment Advisors LLC Has $303,000 Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Nisa Investment Advisors LLC trimmed its holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 4.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,232 shares of the biopharmaceutical company’s stock after selling 190 shares during the period. Nisa Investment Advisors LLC’s holdings in Intra-Cellular Therapies were worth $303,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Healthcare of Ontario Pension Plan Trust Fund raised its position in Intra-Cellular Therapies by 209.4% during the third quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 154,700 shares of the biopharmaceutical company’s stock valued at $8,058,000 after purchasing an additional 104,700 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Intra-Cellular Therapies by 36.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 974,914 shares of the biopharmaceutical company’s stock worth $50,783,000 after buying an additional 259,424 shares during the last quarter. American Century Companies Inc. boosted its stake in Intra-Cellular Therapies by 5.1% in the third quarter. American Century Companies Inc. now owns 441,410 shares of the biopharmaceutical company’s stock valued at $22,993,000 after buying an additional 21,604 shares in the last quarter. Envestnet Asset Management Inc. grew its position in Intra-Cellular Therapies by 56.4% in the third quarter. Envestnet Asset Management Inc. now owns 126,532 shares of the biopharmaceutical company’s stock valued at $6,591,000 after acquiring an additional 45,616 shares during the last quarter. Finally, Emerald Advisers LLC raised its stake in Intra-Cellular Therapies by 13.9% during the third quarter. Emerald Advisers LLC now owns 381,740 shares of the biopharmaceutical company’s stock worth $19,885,000 after acquiring an additional 46,574 shares in the last quarter. 92.33% of the stock is owned by institutional investors and hedge funds.

Intra-Cellular Therapies Stock Down 6.1 %

Intra-Cellular Therapies stock opened at $72.00 on Friday. The company has a market capitalization of $6.97 billion, a PE ratio of -50.38 and a beta of 1.02. Intra-Cellular Therapies, Inc. has a 12-month low of $45.50 and a 12-month high of $84.89. The firm’s fifty day moving average is $69.31 and its 200 day moving average is $63.82.

Intra-Cellular Therapies (NASDAQ:ITCI) last announced its quarterly earnings data on Thursday, February 22nd. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.14. The firm had revenue of $132.10 million for the quarter, compared to analyst estimates of $135.97 million. Intra-Cellular Therapies had a negative net margin of 30.08% and a negative return on equity of 23.02%. The business’s quarterly revenue was up 50.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.45) earnings per share. Sell-side analysts expect that Intra-Cellular Therapies, Inc. will post -0.69 EPS for the current fiscal year.

Analysts Set New Price Targets

ITCI has been the topic of several research reports. Bank of America lifted their price target on shares of Intra-Cellular Therapies from $82.00 to $91.00 and gave the company a “buy” rating in a report on Wednesday. Mizuho boosted their target price on shares of Intra-Cellular Therapies from $76.00 to $82.00 and gave the stock a “buy” rating in a report on Friday, February 16th. Royal Bank of Canada reissued an “outperform” rating and issued a $86.00 price target on shares of Intra-Cellular Therapies in a research note on Wednesday, April 3rd. Robert W. Baird increased their target price on shares of Intra-Cellular Therapies from $83.00 to $103.00 and gave the company an “outperform” rating in a research report on Wednesday. Finally, Needham & Company LLC restated a “buy” rating and issued a $82.00 price target on shares of Intra-Cellular Therapies in a research report on Tuesday. Two equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $86.17.

Insider Buying and Selling

In other Intra-Cellular Therapies news, CEO Sharon Mates sold 20,565 shares of the company’s stock in a transaction on Monday, March 11th. The shares were sold at an average price of $65.21, for a total transaction of $1,341,043.65. Following the transaction, the chief executive officer now owns 1,050,309 shares in the company, valued at $68,490,649.89. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other Intra-Cellular Therapies news, EVP Michael Halstead sold 7,907 shares of the company’s stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $69.53, for a total value of $549,773.71. Following the completion of the sale, the executive vice president now directly owns 29,700 shares of the company’s stock, valued at approximately $2,065,041. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Sharon Mates sold 20,565 shares of Intra-Cellular Therapies stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $65.21, for a total transaction of $1,341,043.65. Following the transaction, the chief executive officer now directly owns 1,050,309 shares in the company, valued at approximately $68,490,649.89. The disclosure for this sale can be found here. In the last three months, insiders have sold 168,487 shares of company stock valued at $11,364,950. 3.40% of the stock is owned by company insiders.

Intra-Cellular Therapies Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.